U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H20FN3O3.CH4O3S
Molecular Weight 453.484
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DANOFLOXACIN MESYLATE

SMILES

CS(O)(=O)=O.CN1C[C@@H]2C[C@H]1CN2C3=CC4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O

InChI

InChIKey=APFDJSVKQNSTKF-FXMYHANSSA-N
InChI=1S/C19H20FN3O3.CH4O3S/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10;1-5(2,3)4/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26);1H3,(H,2,3,4)/t11-,12-;/m0./s1

HIDE SMILES / InChI
Molecular Formula C19H20FN3O3
Molecular Weight 357.3788
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Danofloxacin is a quinolone antibacterial agent for veterinary medicine. The drug is approved by FDA for the treatment of bovine infectious respiratory disease under the name Advocin (mesylate salt). Danofloxacin exerts its action by inhibiting bacterial DNA gyrase.

Originator

Pfizer
420
Curator's Comment: # Pfizer

Approval Year

2002
144
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
ADVOCIN

Approved Use

For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica and Pasteurella multocida and for the control of BRD in beef cattle at high risk of developing BRD associated with Mannheimia haemolytica and Pasteurella multocida.

Launch Date

1.32399366E12
PubMed

PubMed

TitleDatePubMed
Toxic effects of methylmercury, arsanilic acid and danofloxacin on the differentiation of mouse embryonic stem cells into neural cells.
2014
Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and Valnemulin.
2017
Patents

Patents

US4861779 A
2
US5811130 A
2

Sample Use Guides

In Vivo Use Guide
Administered by subcutaneous injection at either 8 mg per kilogram of body weight once or 6 mg per kilogram of body weight with treatment repeated once approximately 48 hours following the first injection.
Route of Administration: Other
In Vitro Use Guide
Danofloxacin minimum inhibitory concentration values (MIC90) were 0.06 ug/mL for both Mannheimia haemolytica and Pasteurella multocida.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:38:18 UTC 2023
Edited
by admin
on Fri Dec 15 16:38:18 UTC 2023
Record UNII
94F3SX3LEM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DANOFLOXACIN MESYLATE
USAN  
USAN  
Official Name English
CP-76,136-27
Code English
DANOFLOXACIN MESYLATE [USAN]
Common Name English
3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-7-(5-METHYL-2,5-DIAZABICYCLO(2.2.1)HEPT-2-YL)-4-OXO-, (1S)-, MONOMETHANESULFONATE
Common Name English
DANOFLOXACIN MESILATE HYDRATE [JAN]
Common Name English
DANOFLOXACIN MESILATE [MART.]
Common Name English
DANOFLOXACIN MESILATE
MART.  
Common Name English
CP-76136-27
Code English
ADVOCID
Brand Name English
DANOFLOXACIN METHANESULFONATE [MI]
Common Name English
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-4-oxo-3-quinolinecarboxylic acid, monomethanesulfonate
Common Name English
DANOFLOXACIN METHANESULFONATE
MI  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C795
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
Code System Code Type Description
SMS_ID
100000172085
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY
PUBCHEM
71334
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY
EPA CompTox
DTXSID30922988
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY
NCI_THESAURUS
C72633
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY
MERCK INDEX
m4082
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY Merck Index
CAS
119478-55-6
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY
FDA UNII
94F3SX3LEM
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY
DRUG BANK
DBSALT002864
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY
DAILYMED
94F3SX3LEM
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY
RXCUI
1358487
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL157548
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY
USAN
BB-50
Created by admin on Fri Dec 15 16:38:18 UTC 2023 , Edited by admin on Fri Dec 15 16:38:18 UTC 2023
PRIMARY
Related Record Type Details
Structure of DANOFLOXACIN
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of DANOFLOXACIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966